From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
CX 717 is a positive allosteric modulator of AMPA receptor. Antidepressant-like effect. CX 717 can be used for the research of adult attention deficit hyperactivity disorder (ADHD) .
CX546 is a first-generation and selective benzamide-type positive AMPAR modulator. CX546 is a prototypical ampakine agent and has antipsychotic effects .
CX-6258 hydrochloride hydrate is a potent and kinase selective pan-Pim kinases inhibitor, with IC50s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively .
CX-5011 free base is a potent CK2 inhibitor. CX-5011 free base also is a Rac-1 activator. CX-5011 free base induces methuosis and promotes macropinocytosis. CX-5011 free base induces apoptosis. CX-5011 free base decreases the expression of rpS6 phosphorylation .
CX-5461 (Standard) is the analytical standard of CX-5461. This product is intended for research and analytical applications. CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively .
CX-6258 hydrochloride is a potent and kinase selective pan-Pim kinases inhibitor, with IC50s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively .
CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively .
CX4338 is a CXCL8-mediated chemokine inhibitor with the activity of inhibiting CXCR2-mediated cell migration. CX4338 selectively inhibits CXCR2-mediated β-arrestin-2 recruitment and receptor internalization while enhancing CXCR2-mediated MAPK activation. CX4338 also inhibited CXCL8-induced chemotaxis, showing efficacy in CXCR2-overexpressing cells and human neutrophils. In vivo, CX4338 significantly reduced LPS-induced neutrophil numbers in mouse bronchoalveolar lavage fluid. The mechanism of action of CX4338 is to selectively inhibit CXCR2-mediated β-arrestin-2 activation, which is sufficient to inhibit CXCL8-mediated chemotaxis .
CX614 is a positive variant modulator of AMPA receptors that enhances excitatory postsynaptic potentials (amplitude and duration) by blocking and slowing the inactivation of responses to glutamate and automatically evokes excitatory postsynaptic currents in neuronal cultures. CX614 can be used in the study of psychiatric disorders such as depression .
CX-5461 dihydrochloride is a potent and orally bioavailable inhibitor of Pol I-mediated rRNA synthesis, with IC50s of 142 nM in HCT-116, 113 nM in A375, and 54 nM in MIA PaCa-2 cells, and shows little or no effect on Pol II (IC50 ≥25 μM).
Quarfloxin (CX-3543), a fluoroquinolone derivative with antineoplastic activity, targets and inhibits RNA pol I activity, with IC50 values in the nanomolar range in neuroblastoma cells. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template .
CX516-d10 is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI)[1].
CX3CL1 Human Pre-designed siRNA Set A contains three designed siRNAs for CX3CL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
CX3CR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CX3CR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cx3cr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cx3cr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
AK 295 (CX 295) is a calpain inhibitor that inhibits apoptosis through a calpain-dependent pathway. AK 295 improves neurological function in a rat model of spinal cord injury (SCI). AK 295 can be used in the study of neurodegenerative diseases, such as bulbar amyotrophy, stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis .
CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .
Tulrampator (S-47445) is an orally active selective AMPA receptor modulator. Tulrampator possesses procognitive, enhancing synaptic plasticity, anti-depressant-anxiolytic-like, procognitive and potential neuroprotective properties. Tulrampator can be used for research of alzheimer’s disease and in major depressive disorder .
Suvecaltamide (MK-8998) is a selective T-type calcium channel inhibitor with oral efficacy. Suvecaltamide exhibits no cytotoxicity in myeloma cell lines and does not affect the antitumor efficacy of Bortezomib (BTZ). Suvecaltamide reverses BTZ-induced peripheral neuropathy (CIPN) in mouse and rat models, and helps inhibit myeloma growth .
SMU-CX1 is a specific TLR3 inhibitor (IC50: 0.11 μM) with IC50 ranging from 0.14-0.33 μM against multiple influenza A virus subtypes. SMU-CX1 inhibits the viral PB2 and NP proteins with an IC50 of 0.43 μM for SARS-CoV-2 activity. SMU-CX1 also inhibits inflammatory factors in host cells, including IFN-β, IP-10, and CCL-5 .
TAT-Gap19, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 traverses the blood-brain barrier and alleviate liver fibrosis in mice .
TAT-Gap19 TFA, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice .
Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial .
Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial .
VRT-534 targets connexin 26 (Cx26). Vrt-534 exhibits dose-responsive binding to recombinant WT Cx26 and mutant Cx26 K188N with EC50 value of 19 μM and 5 μM, respectively. Vrt-534 can be used in research related to hearing impairment .
Rotigaptide (ZP123) is a novel and specific modulator of connexin 43 (Cx43). Rotigaptide prevents the uncoupling of Cx43-mediated gap junction communication and normalizes cell-to-cell communication during acute metabolic stress. Rotigaptide is a potent antiarrhythmic peptide (AAP) with improved stability and has the potential for the investigation of cardiac arrhythmias-specifically atrial fibrillation .
AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with Kis of 3.9 and 2800 nM, respectively .
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells .
JMS-17-2 hydrochloride is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 hydrochloride impairs metastatic seeding and colonization of breast cancer cells .
Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca 2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 µM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .
Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca 2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 µM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .
Cimicoxib (CX) is an orally active potent and selective COX-2 (cyclo-oxygenase-2) inhibitor. Cimicoxib exhibits promising anti-inflammatory and analgesic activity. The PK parameters of Cimicoxib in dogs given precise (2 mg/kg) and approximate doses (1.95-2.5 mg/kg) are similar .
TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. TREM2-IN-1 can relieves immunosuppressive tumor microenvironment and enhancing chemical anticancer efficiency. TREM2-IN-1 deters the tumor growth in mice models bearing MC38 colorectal tumor by reducing the number of CD206 + and CX3CR1+ immunosuppressive macrophages. TREM2-IN-1 also promotes the expansion and infiltration of immunostimulatory dendritic, cytotoxic T and natural killer cells .
TAT-Gap19, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 traverses the blood-brain barrier and alleviate liver fibrosis in mice .
TAT-Gap19 TFA, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice .
Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial .
Connexin mimetic peptide 40,37GAP26 is a biological active peptide. (This peptide corresponds to the GAP26 domain of the extracellular loop of the major vascular connexins (Cx37, Cx40), designated as 37, 40Gap 26 according to Cx homology. It was used to investigate the role of gap junctions in the spread of endothelial hyperpolarizations evoked by cyclopiazonic acid (CPA) through the wall of the rodent iliac artery. The gap junction plaques constructed from Cx37 and Cx40 were abundant in the endothelium. This peptide provides inhibitory effects against subintimal hyperpolarization.)
Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial .
Connexin mimetic peptide 40GAP27 is a biological active peptide. (This peptide corresponds to the GAP27 domain of the second extracellular loop of dominant vascular connexin (Cx40), designated as 40Gap 27. It was used to investigate mechanisms through which oxidant stress impairs communication via gap junctions. When administered, 40Gap27attenuates endothelium-dependent subintimal smooth muscle hyperpolarization.)
SMU-CX1 is a specific TLR3 inhibitor (IC50: 0.11 μM) with IC50 ranging from 0.14-0.33 μM against multiple influenza A virus subtypes. SMU-CX1 inhibits the viral PB2 and NP proteins with an IC50 of 0.43 μM for SARS-CoV-2 activity. SMU-CX1 also inhibits inflammatory factors in host cells, including IFN-β, IP-10, and CCL-5 .
IL-17C is an early response cytokine in the defense against
bacterial pathogens and upregulates the expression of a variety of
antimicrobial peptides. IL-17C stimulates the release of cytokines and is implicated
in autoimmune disorders and bacterial infections. IL-17C
Protein, Human (HEK293, His) is a recombinant human IL-17C protein with His tag
at the C-terminus and is expressed in HEK293 cells.
Fractalkine/CX3CL1 is a chemokine that acts as a ligand to CX3CR1 and the integrins ITGAV: ITGB3 and ITGA4: ITGB1. CX3CL1 promotes lung cancer cell migration and invasion through the Src/FAK signaling pathway. CX3CL1 plays an important role in immune response, inflammation, cell adhesion and chemotaxis. Fractalkine/CX3CL1 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-Avi, C-10*His labeled tag.
The Fractalkine/CX3CL1 protein is a multifunctional chemokine that binds to CX3CR1 and the integrins ITGAV:ITGB3 and ITGA4:ITGB1.It regulates immune responses, inflammation, cell adhesion, and chemotaxis.Fractalkine/CX3CL1 Protein, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
The Fractalkine/CX3CL1 protein is a member of the intercrine beta family and plays a key role in chemokines that are critical for intercellular communication and immune responses. In this family, Fractalkine/CX3CL1 may significantly regulate inflammatory processes and cellular interactions. Fractalkine/CX3CL1 Protein, Canine (HEK293) is the recombinant canine-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with tag free.
IL-17C is an early response cytokine in the defense against
bacterial pathogens and upregulates the expression of a variety of
antimicrobial peptides. IL-17C stimulates the release of cytokines and is implicated
in autoimmune disorders and bacterial infections. IL-17C
Protein, Human (sf9, Fc) is a recombinant human IL-17C protein with hFc tag at
the C-terminus and is expressed in Sf9 insect cells.
The Fractalkine/CX3CL1 protein is a member of the intercrine beta family and plays a key role in chemokines that are critical for intercellular communication and immune responses. In this family, Fractalkine/CX3CL1 may significantly regulate inflammatory processes and cellular interactions. Fractalkine/CX3CL1 Protein, Canine (HEK293, Fc) is the recombinant canine-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-hFc labeled tag.
The Fractalkine/CX3CL1 protein is a member of the intercrine beta family and plays a key role in chemokines that are critical for intercellular communication and immune responses. In this family, Fractalkine/CX3CL1 may significantly regulate inflammatory processes and cellular interactions. Fractalkine/CX3CL1 Protein, Canine (HEK293, His) is the recombinant canine-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-His labeled tag.
The Fractalkine/CX3CL1 protein is a member of the intercrine beta family and plays a key role in chemokines that are critical for intercellular communication and immune responses. In this family, Fractalkine/CX3CL1 may significantly regulate inflammatory processes and cellular interactions. Fractalkine/CX3CL1 Protein, Cynomolgus (317a.a, HEK293, His) is the recombinant cynomolgus-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-His labeled tag.
IL-17C is an early response cytokine in the defense against
bacterial pathogens and upregulates the expression of a variety of
antimicrobial peptides.IL-17C stimulates the release of cytokines and is implicated
in autoimmune disorders and bacterial infections.IL-17C
Protein, Human (HEK293, His-Avi) is a recombinant human IL-17C protein with His
tag and Avi tag at the C-terminus and is expressed in HEK293 cells.
Fractalkine/CX3CL1 protein is a versatile chemokine that acts as a ligand for CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1. It regulates immune response, inflammation, adhesion, and chemotaxis. It activates integrins via CX3CR1-dependent and -independent pathways, binding to site 1 with CX3CR1 and site 2 without CX3CR1. Soluble Fractalkine/CX3CL1 attracts T-cells and monocytes, not neutrophils. Fractalkine/CX3CL1 Protein, Rat is the recombinant rat-derived Fractalkine/CX3CL1 protein, expressed by E. coli , with tag free. The total length of Fractalkine/CX3CL1 Protein, Rat is 79 a.a., with molecular weight of ~11 kDa.
IL-17C is an early response cytokine in the defense against
bacterial pathogens and upregulates the expression of a variety of
antimicrobial peptides. IL-17C stimulates the release of cytokines and is implicated
in autoimmune disorders and bacterial infections. IL-17C
Protein, Human (Biotinylated, HEK293, His-Avi) is a biotinylated recombinant human
IL-17C protein with His tag and Avi tag at the C-terminus and is expressed in
HEK293 cells.
The Fractalkine/CX3CL1 protein is a multifunctional chemokine that binds to CX3CR1 and the integrins ITGAV:ITGB3 and ITGA4:ITGB1.It regulates immune responses, inflammation, cell adhesion, and chemotaxis.Fractalkine/CX3CL1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-6*His labeled tag.
Fractalkine/CX3CL1 protein, a chemokine, binds CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1. It regulates immune response, inflammation, adhesion, chemotaxis, and leukocyte migration. It activates integrins via CX3CR1-dependent and -independent pathways, binding to site 1 with CX3CR1 and site 2 without CX3CR1. Soluble Fractalkine/CX3CL1 attracts T-cells and monocytes, not neutrophils. Fractalkine/CX3CL1 Protein, Cynomolgus (HEK293, Fc) is the recombinant Cynomolgus-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-hFc labeled tag.
Fractalkine/CX3CL1 protein, a chemokine, binds CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1. It regulates immune response, inflammation, adhesion, chemotaxis, and leukocyte migration. It activates integrins via CX3CR1-dependent and -independent pathways, binding to site 1 with CX3CR1 and site 2 without CX3CR1. Soluble Fractalkine/CX3CL1 attracts T-cells and monocytes, not neutrophils. Fractalkine/CX3CL1 Protein, Cynomolgus (HEK293, His) is the recombinant Cynomolgus-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-His labeled tag.
Fractalkine/CX3CL1 protein, a chemokine, binds CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1. It regulates immune response, inflammation, adhesion, chemotaxis, and leukocyte migration. It activates integrins via CX3CR1-dependent and -independent pathways, binding to site 1 with CX3CR1 and site 2 without CX3CR1. Soluble Fractalkine/CX3CL1 attracts T-cells and monocytes, not neutrophils. Fractalkine/CX3CL1 Protein, Human (315a.a, HEK293, His) is the recombinant human-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-His labeled tag. The total length of Fractalkine/CX3CL1 Protein, Human (315a.a, HEK293, His) is 315 a.a., with molecular weight of 50-90 kDa.
CNR2 Protein-VLP, a heterotrimeric G protein-coupled receptor, crucially inhibits adenylate cyclase, mediating functions in inflammatory responses, nociceptive transmission, and bone homeostasis. Its modulation of cellular signaling underscores its significance in physiological processes, positioning CNR2 Protein-VLP as a key regulator in inflammatory, sensory mechanisms, and bone equilibrium. CNR2 Protein, Human (Cell-Free, His) is the recombinant human-derived CNR2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of CNR2 Protein, Human (Cell-Free, His) is 360 a.a., with molecular weight of 42.5 kDa.
The GJA1 protein regulates bladder capacity through gap junctions, clusters of transmembrane channels that allow the diffusion of low molecular weight materials between adjacent cells. GJA1 protein also regulates NOV expression and localization and is important for ventricular gap junction communication. GJA1 Protein, Human (His) is the recombinant human-derived GJA1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of GJA1 Protein, Human (His) is 150 a.a., with molecular weight of ~22 kDa.
IL-17B
is a proinflammatory cytokine and stimulates the release of tumour necrosis
factor alpha (TNFα) and IL-1β. IL-17B plays an important role in cancer
progression, angiogenesis, and inflammatory arthritis.
IL-17B Protein, Mouse (His) is a recombinant mouse IL-17B protein with His tag at
the N-terminus and is expressed in E. coli. It consists of 160
amino acids (H21-F180).
IL-17B Proteinas, a key immune response regulator, stimulates THP-1 monocytic cells to release pro-inflammatory cytokines, TNF-α, and IL-1β. Its crucial role in orchestrating immune reactions and inflammatory pathways positions it as a potential modulator of immune homeostasis, making it a therapeutic intervention target for regulating inflammatory processes. Animal-Free IL-17B Protein, Mouse (His) is the recombinant mouse-derived animal-FreeIL-17B protein, expressed by E. coli , with C-His, C-His labeled tag. The total length of Animal-Free IL-17B Protein, Mouse (His) is 160 a.a., with molecular weight of ~18.99 kDa.
CX516-d10 is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI)[1].
Connexin 43; Connexin-43; Cx 43; Cx43; CxA1_HUMAN; DFNB38; Gap junction 43 kDa heart protein; Gap junction alpha-1 protein; Gap junction protein alpha 1 43kDa (connexin 43); Gap junction protein alpha 1 43kDa; Gap junction protein alpha like; GJA 1; Gja1
WB, IHC-F, IHC-P, ICC/IF, ELISA
Human, Mouse, Rat
Connexin 43 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 43 kDa, targeting to Connexin 43. It can be used for WB,IHC-F,IHC-P,ICC/IF,ELISA assays with tag free, in the background of Human, Mouse, Rat.
Connexin 32 Antibody (YA2960) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2960), targeting Connexin 32, with a predicted molecular weight of 32 kDa (observed band size: 32 kDa). Connexin 32 Antibody (YA2960) can be used for WB, IHC-P, FC experiment in human background.
CX3CL1 Human Pre-designed siRNA Set A contains three designed siRNAs for CX3CL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
CX3CR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CX3CR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cx3cr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cx3cr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
